Clinical trial
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients…
NCT00266097 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00266097 |
|---|---|
| Title | Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer |
| Official title | A Two-Part Phase I Study of the Addition of Oxaliplatin to Gemcitabine, and Then Erlotinib Plus Oxaliplatin to Gemcitabine as Radiosensitizers for Pancreatic and Biliary Adenocarcinoma |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer |
| Intervention type | Drug, Radiation |
| Interventions | erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, radiation therapy, Oxaliplatin |
| Enrollment | 23 |
| Start date | Aug 1, 2004 |
| Primary completion | Mar 1, 2009 |
| Completion | Sep 1, 2011 |
| First posted | Dec 15, 2005 |
| Last update posted | Mar 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: